NeoGenomics (NASDAQ:NEO) had its price target lifted by analysts at Royal Bank of Canada from $23.00 to $24.00 in a research note issued to investors on Tuesday. The brokerage currently has an “outperform” rating on the medical research company’s stock. Royal Bank of Canada’s price target points to a potential upside of 187.43% from the stock’s previous close.
Several other research firms have also recently weighed in on NEO. BidaskClub cut NeoGenomics from a “buy” rating to a “hold” rating in a report on Thursday, December 21st. Scotiabank set a $22.00 price objective on NeoGenomics and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. CIBC set a $19.00 price objective on NeoGenomics and gave the stock a “neutral” rating in a report on Wednesday, January 3rd. ValuEngine cut NeoGenomics from a “hold” rating to a “sell” rating in a report on Wednesday, March 7th. Finally, Zacks Investment Research upgraded NeoGenomics from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. NeoGenomics currently has a consensus rating of “Hold” and a consensus target price of $17.29.
Shares of NeoGenomics (NASDAQ:NEO) opened at $8.35 on Tuesday. NeoGenomics has a fifty-two week low of $7.08 and a fifty-two week high of $11.63. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.99. The firm has a market capitalization of $685.92, a P/E ratio of 142.00, a price-to-earnings-growth ratio of 4.73 and a beta of 0.47.
NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Wednesday, February 21st. The medical research company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.02. NeoGenomics had a positive return on equity of 4.37% and a negative net margin of 1.37%. The business had revenue of $67.79 million during the quarter, compared to analysts’ expectations of $66.32 million. During the same quarter last year, the business posted $0.05 EPS. The business’s revenue was up 12.1% on a year-over-year basis. sell-side analysts forecast that NeoGenomics will post 0.09 earnings per share for the current year.
Several large investors have recently made changes to their positions in the company. BlackRock Inc. raised its position in shares of NeoGenomics by 1.4% in the 4th quarter. BlackRock Inc. now owns 3,952,796 shares of the medical research company’s stock worth $35,022,000 after acquiring an additional 54,998 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of NeoGenomics by 50.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,464,655 shares of the medical research company’s stock worth $38,562,000 after acquiring an additional 1,159,888 shares in the last quarter. Vanguard Group Inc. raised its position in shares of NeoGenomics by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 2,724,603 shares of the medical research company’s stock worth $24,413,000 after acquiring an additional 44,820 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of NeoGenomics by 25.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,496,623 shares of the medical research company’s stock worth $27,786,000 after acquiring an additional 499,913 shares in the last quarter. Finally, Emerald Advisers Inc. PA raised its position in shares of NeoGenomics by 3.1% in the 4th quarter. Emerald Advisers Inc. PA now owns 1,424,263 shares of the medical research company’s stock worth $12,619,000 after acquiring an additional 42,790 shares in the last quarter. 84.72% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “NeoGenomics (NEO) PT Raised to $24.00 at Royal Bank of Canada” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/03/15/neogenomics-neo-pt-raised-to-24-00-at-royal-bank-of-canada.html.
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.